글로벌 상피 성장 인자 수용체 억제제 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 상피 성장 인자 수용체 억제제 시장

상피 성장 인자 수용체 억제제 시장 규모는 2021년부터 2028년까지의 예측 기간 동안 연평균 성장률 9.0%로 성장할 것으로 예상됩니다. Data Bridge Market Research의 상피 성장 인자 수용체 억제제 시장 보고서는 예측 기간 동안 널리 퍼질 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다.

상피 성장 인자 수용체는 일반적으로 세포 성장을 담당하는 막 관통 단백질 로 , 수용체를 차단하고 장기간 세포 성장을 억제하며 주로 폐암, 간암, 유방암, 담보암 등의 치료에 사용됩니다. 암세포의 통제되지 않는 세포 성장은 이러한 단백질을 생산하는 책임 유전자의 돌연변이로 인해 상피 성장 인자 수용체 수치가 높은 것이 특징입니다.

새로운 EGFR 억제제에 대한 고도의 연구 개발과 전 세계적으로 증가하는 암 발병률은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 가속화할 것으로 예상됩니다. 이에 더하여, 가혹한 생활 방식의 채택과 알코올 및 담배 소비 증가는 암의 수를 증가시켜 시장 수요를 더욱 촉진합니다.

그러나 치료법과 대체 치료법의 가용성과 관련된 높은 비용은 시장 성장률을 제한할 것으로 예상됩니다. 또한, 다양한 질병 상태를 개발하는 노인 인구가 증가함에 따라 EGFR 억제제 치료법이 다양한 새로운 기회를 창출할 가능성이 높으며, 이는 2021년에서 2028년 예측 기간 동안 이 상피 성장 인자 수용체 억제제 시장 성장에 영향을 미칠 것입니다. 잠재력의 임상적 실패는 시장 성장에 도전할 것으로 추정됩니다.

This epidermal growth factor receptor inhibitors market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the epidermal growth factor receptor inhibitors market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Epidermal Growth Factor Receptor Inhibitors Market Scope and Market Size

Epidermal growth factor receptor inhibitors market is segmented on the basis of application, drugs, route of administration, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of application, the market is segmented into lung cancer, liver cancer, breast cancer and others.
• On the basis of drugs, the epidermal growth factor receptor inhibitors market is segmented into cetuximab, erlotinib, gefitinib and others.
• On the basis of route of administration, the epidermal growth factor receptor inhibitors market is segmented into oral, injectable and others.
• Based on end users, the market is segregated into hospitals, homecare, specialty clinics and others.
• On the basis of distribution channel, the epidermal growth factor receptor inhibitors market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

Epidermal Growth Factor Receptor Inhibitors Market Country Level Analysis

Epidermal growth factor receptor inhibitors market is analyzed and market size information is provided by country, application, drugs, route of administration, end users and distribution channel as referenced above.

The countries covered in the epidermal growth factor receptor inhibitors market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the epidermal growth factor receptor inhibitors market due to the availability of medicines for the treatment and highly developed health infrastructure. The Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of various patient programs from both the vendors and the governments in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Epidermal growth factor receptor inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive landscape and global epidermal growth factor receptor inhibitors market share analysis

Epidermal growth factor receptor inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to epidermal growth factor receptor inhibitors market.

상피 성장 인자 수용체 억제제 시장 보고서에 포함된 주요 기업은 AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Spectrum Pharmaceuticals, Inc., CULLINAN ONCOLOGY, LLC, TAIHO PHARMACEUTICAL CO., LTD., Lutris Pharma, Boehringer Ingelheim International GmbH, Puma Biotechnology, IncApollomics, Inc., Hutchison MediPharma Limited, Genentech, Inc., ASLAN Pharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, Hutchison China MediTech Limited, Sihuan Pharmaceutical Holdings Group Ltd, Astellas Pharma Inc., Celldex Therapeutics, YUHAN, Johnson & Johnson Services, Inc 등 국내 및 글로벌 기업입니다. 상피 성장 인자 수용체 억제제 시장 점유율 데이터는 글로벌, 북미, 남미, 유럽, 아시아 태평양(APAC) 및 중동 및 아프리카(MEA)에 대해 별도로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

SKU-50344